Long-term in vitro correction of alpha-L-iduronidase deficiency (Hurler syndrome) in human bone marrow.
AuthorsFairbairn, Leslie J
Lashford, Linda S
McDermott, R H
Arrand, Jane E
Arrand, John R
Hatton, C E
Besley, G T
Wraith, J Ed
Anson, D S
Hopwood, J J
Dexter, T Michael
AffiliationDepartment of Experimental Haematology, Paterson Institute for Cancer Research, Christie Hospital National Health Service Trust, Manchester, United Kingdom.
MetadataShow full item record
AbstractAllogeneic bone marrow transplantation is the most effective treatment for Hurler syndrome but, since this therapy is not available to all patients, we have considered an alternative approach based on transfer and expression of the normal gene in autologous bone marrow. A retroviral vector carrying the full-length cDNA for alpha-L-iduronidase has been constructed and used to transduce bone marrow from patients with this disorder. Various gene-transfer protocols have been assessed including the effect of intensive schedules of exposure of bone marrow to viral supernatant and the influence of growth factors. With these protocols, we have demonstrated successful gene transfer into primitive CD34+ cells and subsequent enzyme expression in their maturing progeny. Also, by using long-term bone marrow cultures, we have demonstrated high levels of enzyme expression sustained for several months. The efficiency of gene transfer has been assessed by PCR analysis of hemopoietic colonies as 25-56%. No advantage has been demonstrated for the addition of growth factors or intensive viral exposure schedules. The enzyme is secreted into the medium and functional localization has been demonstrated by reversal of the phenotypic effects of lysosomal storage in macrophages. This work suggests that retroviral gene transfer into human bone marrow may offer the prospect for gene therapy of Hurler syndrome in young patients without a matched sibling donor.
CitationLong-term in vitro correction of alpha-L-iduronidase deficiency (Hurler syndrome) in human bone marrow. 1996, 93 (5):2025-30 Proc. Natl. Acad. Sci. U.S.A.
JournalProceedings of the National Academy of Sciences of the United States of America
- Towards gene therapy of Hurler syndrome.
- Authors: Fairbairn LJ, Lashford LS, Spooncer E, McDermott RH, Lebens G, Arrand JE, Arrand JR, Bellantuono I, Holt R, Hatton CE, Cooper A, Besley GT, Wraith JE, Anson DS, Hopwood JJ, Dexter TM
- Issue date: 1997 Jan 8
- Retrovirus-mediated transfer of the human alpha-L-iduronidase cDNA into human hematopoietic progenitor cells leads to correction in trans of Hurler fibroblasts.
- Authors: Huang MM, Wong A, Yu X, Kakkis E, Kohn DB
- Issue date: 1997 Nov
- Gene therapy for canine alpha-L-iduronidase deficiency: in utero adoptive transfer of genetically corrected hematopoietic progenitors results in engraftment but not amelioration of disease.
- Authors: Lutzko C, Omori F, Abrams-Ogg AC, Shull R, Li L, Lau K, Ruedy C, Nanji S, Gartley C, Dobson H, Foster R, Kruth S, Dubé ID
- Issue date: 1999 Jun 10
- Genetically corrected autologous stem cells engraft, but host immune responses limit their utility in canine alpha-L-iduronidase deficiency.
- Authors: Lutzko C, Kruth S, Abrams-Ogg AC, Lau K, Li L, Clark BR, Ruedy C, Nanji S, Foster R, Kohn D, Shull R, Dubé ID
- Issue date: 1999 Mar 15
- Treatment of the mouse model of mucopolysaccharidosis I with retrovirally transduced bone marrow.
- Authors: Zheng Y, Rozengurt N, Ryazantsev S, Kohn DB, Satake N, Neufeld EF
- Issue date: 2003 Aug